Vijendra K. Singh

Vijendra K. Singh, Ph.D., is an independent Scientific Consultant for Neuro-Immune Biosystems. Dr. Singh's research has focused on pathogenetic mechanisms and therapeutic strategies of brain diseases and mental illnesses, in particular autism, Alzheimer's disease, stress, depression and related health conditions. He is a former university professor of neuroimmunology research from the University of Michigan, Utah State University, Medical University of South Carolina and University of British Columbia. His expertise also extends into alternative approaches including immune modulators and nutraceutical supplements.
Academic Background
Dr. Singh, a graduate of Lucknow University in India, received his doctorate from the University of British Columbia in Vancouver, BC, Canada. At UBC, he did his post-doctoral fellowship in neurochemistry and immunology. At BC’s Children’s Hospital in Vancouver, he specialized in clinical immunology, laboratory medicine and neuroimmunology. He is an active member of the Society for Neuroscience (SfN), American Academy of Anti-Aging Medicine (A4M), and American Academy of Neurology (AAN) and former member of American Association for the Advancement of Science (AAAS), American Association of Immunologists (AAI) and American Society for Microbiology (ASM). He is also a member of prestigious International Who’s Who of Intellectuals (UK) and American Men and Women in Science (USA). He has also served on scientific advisory board of several non-profit organizations, including Brain State International Research Center, Autism Autoimmunity Project, MIND Institute, and Center for Autistic Disorders. Dr. Singh has also been recognized with humanitarian award - O. Spurgeon English Humanitarian Award from Psychiatric Association of Philadelphia and National Foundation for Alternative Medicine (NFAM), Washington, DC. He serves on the Health Science Advisory Board of 4Life Research, Inc., which manufactures natural immunomodulator called Transfer Factor (TF) and other TF-containing protudcts. He briefly worked to compile research at Brain State Technologies, Inc., a company that claims to improve a number of life conditions through brain training. Dr. Singh left the company in 2010.
Research Focus
Dr. Singh possesses nearly forty years of experience in neurobiology and immunology research, beginning at the BC Children's Hospital in Vancouver, British Columbia, where he focused on neurochemistry and immunology of the nervous system. After moving to the United States, he continued researching central nervous system (CNS) disorders at the University of Michigan, Utah State University, and Medical University of South Carolina. He pioneered the role of immune system in Alzheimer's disease and autism .
The cause of autism is not well understood. Dr. Singh was one of the first to hypothesize the role of autoimmunity in Alzheimer's disease and autism and published scientific evidence through laboratory research in support of that hypothesis. This led to the concept of immune modulation therapy (IMT) for these disorders.
Dr. Singh has devoted his entire career to scholarly research on brain diseases and mental illnesses - neuropathologies that includes autism spectrum disorders (ASD), multiple sclerosis (MS), and Alzheimer’s disease (AD), stress hormones, brain trauma, clinical depression, Tourette’s syndrome and obsessive-compulsive disorder (OCD). He has specialized in the biochemistry and immunology of central nervous system (CNS) diseases and neuro-immune-dysfunction syndromes (NIDS). His academic profile also includes 250 papers and presentations. He continues to lead neuroscience research for causation and treatment of brain diseases and mental health problems across the lifespan. The focus of research is on biological, environmental and nutritional factors and how they impact the function of immune system and nervous system in man. He pioneered the role of autoimmunity in autism identifying “Autoimmune Autistic Disorder (AAD)” and opened a novel window of opportunity to help autistic children with immune modulation therapy, including intravenous immumoglobulin (IV-IG) and Transfer Factor.
< Prev   Next >